Celularity Inc revenue
Celularity Inc's revenue was $26.6m in fiscal 2025, down 51.0% on the year before. Since fiscal 2020 ($14.3m) it has grown at a compound 13.2% a year. Over the last twelve months it was $18.7m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Degenerative Disease | $17.3M | 65.2% | ▼ 64.2% |
| Biobanking | $5.4M | 20.5% | ▲ 5.7% |
| Cell Therapy | $3.8M | 14.3% | ▲ 453.3% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $13.2M | 49.6% | ▼ 62.7% |
| License Royalty and Other | $7.9M | 29.9% | ▼ 42.2% |
| Services | $5.4M | 20.5% | ▲ 5.7% |
From Celularity Inc's 10-K filed April 30, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Celularity Inc | $18.7m | -58.1% | 7.2% |
| Cytomx Therapeutics, Inc. | $18.3m | -87.0% | -38.7% |
| Scynexis Inc | $19.2m | 489.8% | -47.9% |
| Proqr Therapeutics N.V. | $18.0m | -12.1% | — |
| Keros Therapeutics, Inc. | $14.9m | -93.6% | — |
| Janux Therapeutics, Inc. | $24.0m | 5367.0% | 45.7% |
Compare with peers
- Cytomx Therapeutics, Inc. revenue
- Scynexis Inc revenue
- Proqr Therapeutics N.V. revenue
- Keros Therapeutics, Inc. revenue
- Janux Therapeutics, Inc. revenue
Head to head: CELU vs CTMXCELU vs SCYXCELU vs PRQR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies